Ohr Pharmaceutical Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ohr Pharmaceutical Inc.
Rise In Securities Class Action Filings In Life Sciences Sector
Last year proved to be another record period for securities class actions, with a 13% increase in cases filed compared with 2018, and a 24% increase in claims brought against life sciences companies compared with 2018, according to a report by Cornerstone Research: Securities Class Action Filings: 2019 Year In Review.
Appointments: BMS CCO Leaves, New Medical Heads At Astellas Americas, Epizyme, CEOs At NanoViricides, Aeglea, Waverley Pharma
Bristol-Myers Squibb's CCO Murdo Gordon has exited the company in the week of its Q2 results, while Trevi Therapeutics, Turnstone Biologics, Aeglea BioTherapeutics, Acadia Pharmaceuticals, NanoViricides and Waverley Pharmaceuticals add to their C-suite. Medical heads join Epizyme and Astellas Americas.
Pipeline Watch: Phase III Readouts For Eptinezumab, KPI-121 And Omidenepag Isopropyl
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Deals Shaping The Medical Industry, May 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2017.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.